Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy

Assiut University75 enrolled

Overview

Diabetes mellitus is a chronic disease that affects 366 million people worldwide ( 6.4 % of the adult population ) and is expected to rise to 522 million by 2030 . Diabetic nephropathy occurs in approximately one - third of all people with diabetes and is the leading cause of renal failure in developed and developing countries Diabetic nephropathy is a severe complication occurring in diabetic patients and it is associated with an increased risk of all- cause mortality , cardiovascular disease and progression to end stage renal disease , requiring costly renal replacement therapy in the form of dialysis or transplantation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Diabetic Nephropathies

Interventions

serum immunoglobulin G levelDIAGNOSTIC_TEST

measurement of the serum level as a marker of diabetic complications

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * type 2 diabetic patients Exclusion Criteria: * patients with diabetes type 1 , * pregnant and lactating females , * patients with any congenital disease , Infection , Smokers , alcoholics , and drug abusers .

Outcomes

Primary Outcomes

The number of patients with high level of immunoglobulin in serum

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.